Aptamer Group plc Stock

Equities

APTA

GB00BNRRP542

Advanced Medical Equipment & Technology

Market Closed - London S.E. 11:35:05 2024-05-28 am EDT 5-day change 1st Jan Change
0.8 GBX 0.00% Intraday chart for Aptamer Group plc +18.52% -30.43%
Sales 2022 4.04M 5.15M Sales 2023 1.75M 2.24M Capitalization 4.66M 5.95M
Net income 2022 -2M -2.55M Net income 2023 -7M -8.93M EV / Sales 2022 15.1 x
Net cash position 2022 5.38M 6.87M Net Debt 2023 844K 1.08M EV / Sales 2023 3.14 x
P/E ratio 2022
-29.6 x
P/E ratio 2023
-0.59 x
Employees 37
Yield 2022 *
-
Yield 2023
-
Free-Float 68.34%
More Fundamentals * Assessed data
Dynamic Chart
1 week+18.52%
Current month+10.34%
1 month+6.67%
3 months+3.23%
6 months-31.91%
Current year-30.43%
More quotes
1 week
0.75
Extreme 0.751
0.94
1 month
0.61
Extreme 0.61
0.94
Current year
0.45
Extreme 0.45
1.40
1 year
0.45
Extreme 0.45
30.50
3 years
0.45
Extreme 0.45
157.00
5 years
0.45
Extreme 0.45
157.00
10 years
0.45
Extreme 0.45
157.00
More quotes
Managers TitleAgeSince
Founder - 07-12-31
Founder 46 07-12-31
Director of Finance/CFO - 21-12-31
Members of the board TitleAgeSince
Director/Board Member 59 23-08-20
Founder 46 07-12-31
Founder - 07-12-31
More insiders
Date Price Change Volume
24-05-28 0.8 0.00% 8 726 653
24-05-24 0.8 0.00% 1,549,899
24-05-23 0.8 +3.23% 12,242,900
24-05-22 0.775 +14.81% 12,587,600
24-05-21 0.675 0.00% 1,070,032

Delayed Quote London S.E., May 28, 2024 at 11:35 am EDT

More quotes
Aptamer Group plc is a United Kingdom-based company that develops custom affinity binders through its Optimer platform to enable new approaches in therapeutics, diagnostics and research applications. The Company's Optimer platform delivers next-generation aptamer tools that are enabling researchers and developers across the spectrum of the life sciences. Its Optimer binders have been developed for a range of applications, including therapeutic inhibitors and modulators, drug delivery vehicles, protein purification and separation, biomarker screening and validation, in vitro research, quality control analysis, pharmacokinetic and drug assays, and in vitro diagnostic assays. Its Aptamer Diagnostics division uses the Company's technology to support the development of diagnostic platforms, such as proteomics, lateral flow devices, biosensors and immunoassays, such as enzyme-linked immunosorbent assay (ELISA). Its Optimer platform supports a diverse portfolio of partners and technologies.
More about the company

Annual profits - Rate of surprise